Cases & Deals

Astellas and Agensys prosecute patent portfolios for novel monoclonal antibody and antibody-drug conjugate immunotherapeutics useful for certain cancer treatments

Clients Astellas Pharma Inc. and Agensys, Inc.

Jones Day represents Astellas Pharma Inc. and its subsidiary Agensys, Inc. in prosecuting their worldwide patent portfolios related to novel monoclonal antibody and antibody-drug conjugate (ADC) immunotherapeutics for use in the treatment of a variety of cancer indications, including PADCEV®, an ADC approved by the FDA in 2019 for the treatment of metastatic bladder cancer.